Stocks and Investing
Stocks and Investing
Thu, October 14, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Berens Initiated (CCCC) at Buy and Held Target at $67 on, Oct 14th, 2021
Andrew Berens of SVB Leerink, Initiated "C4 Therapeutics, Inc." (CCCC) at Buy and Held Target at $67 on, Oct 14th, 2021.
Andrew has made no other calls on CCCC in the last 4 months.
There are 2 other peers that have a rating on CCCC. Out of the 2 peers that are also analyzing CCCC, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Bradley Canino of "Stifel" Initiated at Hold and Held Target at $45 on, Thursday, September 30th, 2021
This is the rating of the analyst that currently disagrees with Andrew
- Leah Cann of "Brookline Capital" Initiated at Strong Buy and Held Target at $54 on, Thursday, June 24th, 2021
Contributing Sources